Yehudawexler (Talk | contribs) |
|||
(38 intermediate revisions by 5 users not shown) | |||
Line 7: | Line 7: | ||
<meta charset="utf-8"> | <meta charset="utf-8"> | ||
+ | <meta name="viewport" content="width=device-width, initial-scale=1"> | ||
+ | |||
<script> | <script> | ||
Line 32: | Line 34: | ||
</script> | </script> | ||
− | + | <style> | |
+ | .Tspeacial { | ||
+ | font-size:200%; | ||
+ | color:#DC5E22; | ||
+ | font-weight:bold; | ||
+ | } | ||
+ | </style> | ||
</head> | </head> | ||
Line 41: | Line 49: | ||
− | + | ||
− | + | ||
− | + | ||
− | + | <br> | |
<div class = "col-md-offset-2 col-md-8" > | <div class = "col-md-offset-2 col-md-8" > | ||
− | + | <div class= "row"> | |
− | + | <div class = "col-md-12" > | |
+ | |||
+ | <br> | ||
+ | <br> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/d/df/T--TECHNION-ISRAEL--Terminate_header.png" class="cover" alt="" style= "width:30% ; margin: auto;"> | ||
+ | <br> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/7/7f/T--TECHNION-ISRAEL--bomb_header.png" class="cover" alt="" style= "width:10% ; margin: auto;"> | ||
+ | <br><br> | ||
+ | <h4 style="text-align:center;"> | ||
+ | Ganciclovir Kill Switch | ||
+ | </h4> | ||
+ | |||
+ | |||
+ | |||
<p> | <p> | ||
− | In light of our <a href="https://2017.igem.org/Team:TECHNION-ISRAEL/delay_mechanism">delay mechanism</a> epitopes are displayed on the cellular membrane only after engraftment within the bone marrow. Unfortunately no biologically inducible system is perfect and there will always be a basal level of “leakiness”. Additionally, bone marrow cells routinely migrate to the bloodstream. For this reason, as well as ethical considerations, we have implemented a "Kill switch" based on the use of the Ganciclovir prodrug and transfection of the Herpes Simplex Virus – Thymidine Kinase (HSV-TK). | + | In light of our <a target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/delay_mechanism">delay mechanism</a> epitopes are displayed on the cellular membrane only after engraftment within the bone marrow. Unfortunately no biologically inducible system is perfect and there will always be a basal level of “leakiness”. Additionally, bone marrow cells routinely migrate to the bloodstream. For this reason, as well as ethical considerations, we have implemented a "Kill switch" based on the use of the Ganciclovir prodrug and transfection of the Herpes Simplex Virus – Thymidine Kinase (HSV-TK). |
</p> | </p> | ||
<br> | <br> | ||
Line 58: | Line 79: | ||
</sup> | </sup> | ||
experimental and clinical methods for Gene-Directed Enzyme Prodrug Therapy (GDEPT). | experimental and clinical methods for Gene-Directed Enzyme Prodrug Therapy (GDEPT). | ||
− | + | The concept of GDEPT has existed for over 20 years, but its clinical importance has grown exponentially in the past 5 years with more and more GDEPT based systems entering clinical trials. GDEPT systems are comprised of three components: An inactive drug (“prodrug”), a gene coding for an enzyme that converts the inactive prodrug to an active drug, and a delivery mechanism. Ideally, the prodrug should be non-toxic or minimally toxic prior to activation by enzyme but highly toxic after enzymatic activation | |
− | + | <sup id = "cite ref-1 " class ="reference"> | |
− | + | ||
<a href="#ref1" original-title>[1] </a> | <a href="#ref1" original-title>[1] </a> | ||
</sup>. | </sup>. | ||
Line 66: | Line 86: | ||
<br> | <br> | ||
− | |||
− | |||
− | |||
− | <p>As shown below expression of HSV-TK gene leads to the synthesis of viral thymidine kinases. These kinases convert GCV into GCV monophosphate which is subsequently converted into a toxic triphosphate form by natural cellular kinases. GCV triphosphate is analogous to 2'-deoxyguanosine triphosphate (dGTP) and therefore incorporates into replicating DNA causing premature strand termination, replication failure and apoptosis | + | <p>As shown below expression of HSV-TK gene leads to the synthesis of viral thymidine kinases. These kinases convert GCV into GCV monophosphate which is subsequently converted into a toxic triphosphate form by natural cellular kinases. GCV triphosphate is analogous to 2'-deoxyguanosine triphosphate (dGTP) and therefore incorporates into replicating DNA causing premature strand termination, replication failure and apoptosis <strong> (Figure 1)</strong> |
<sup id = "cite ref-2 " class ="reference"> | <sup id = "cite ref-2 " class ="reference"> | ||
<a href="#ref2" original-title>[2] </a> | <a href="#ref2" original-title>[2] </a> | ||
Line 79: | Line 96: | ||
<img class= "img-responsive img-center" src="https://static.igem.org/mediawiki/2017/1/1f/T--TECHNION-ISRAEL--guncic3.png" alt="" style= "width:100% ; margin: auto;"> | <img class= "img-responsive img-center" src="https://static.igem.org/mediawiki/2017/1/1f/T--TECHNION-ISRAEL--guncic3.png" alt="" style= "width:100% ; margin: auto;"> | ||
<br> | <br> | ||
− | <p style="text-align: center;"> <strong>Figure 1:</strong> </p> | + | <p style="text-align: center;"> <strong>Figure 1:</strong> The Ganciclovir System </p> |
<br> | <br> | ||
<br> | <br> | ||
<br> | <br> | ||
− | <p> <strong>Our goal </strong> is to add an additional cistron, which will code for HSV-TK, to our display mechanism. Accordingly, transfected HSCs expressing epitope will concurrently express HSV-TK. In the case of an allergic reaction, or patient dissatisfaction, treatment with Ganciclovir will induce apoptosis in all epitope expressing HSCs. | + | <p> <strong>Our goal </strong> is to add an additional cistron, which will code for HSV-TK, to our <a target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/Design">display mechanism.</a> Accordingly, transfected HSCs expressing epitope will concurrently express HSV-TK. In the case of an allergic reaction, or patient dissatisfaction, treatment with Ganciclovir will induce apoptosis in all epitope expressing HSCs. |
</p> | </p> | ||
<br> | <br> | ||
Line 99: | Line 116: | ||
</div> | </div> | ||
− | <a id="back-to-top" href="#" class="btn btn-lg back-to-top" role="button | + | <a id="back-to-top" href="#" class="btn btn-lg back-to-top" role="button"><img src="https://static.igem.org/mediawiki/2017/f/f9/T--TECHNION-ISRAEL--newUpAB.png" alt=""></a> |
</body> | </body> | ||
</html> | </html> | ||
{{:Team:TECHNION-ISRAEL/sponsors}} | {{:Team:TECHNION-ISRAEL/sponsors}} |
Latest revision as of 02:01, 2 November 2017
![](https://static.igem.org/mediawiki/2017/d/df/T--TECHNION-ISRAEL--Terminate_header.png)
![](https://static.igem.org/mediawiki/2017/7/7f/T--TECHNION-ISRAEL--bomb_header.png)
Ganciclovir Kill Switch
In light of our delay mechanism epitopes are displayed on the cellular membrane only after engraftment within the bone marrow. Unfortunately no biologically inducible system is perfect and there will always be a basal level of “leakiness”. Additionally, bone marrow cells routinely migrate to the bloodstream. For this reason, as well as ethical considerations, we have implemented a "Kill switch" based on the use of the Ganciclovir prodrug and transfection of the Herpes Simplex Virus – Thymidine Kinase (HSV-TK).
Transfection of HSV-TK, followed by treatment with the prodrug ganciclovir (GCV), is one of the most commonly used [1] experimental and clinical methods for Gene-Directed Enzyme Prodrug Therapy (GDEPT). The concept of GDEPT has existed for over 20 years, but its clinical importance has grown exponentially in the past 5 years with more and more GDEPT based systems entering clinical trials. GDEPT systems are comprised of three components: An inactive drug (“prodrug”), a gene coding for an enzyme that converts the inactive prodrug to an active drug, and a delivery mechanism. Ideally, the prodrug should be non-toxic or minimally toxic prior to activation by enzyme but highly toxic after enzymatic activation [1] .
As shown below expression of HSV-TK gene leads to the synthesis of viral thymidine kinases. These kinases convert GCV into GCV monophosphate which is subsequently converted into a toxic triphosphate form by natural cellular kinases. GCV triphosphate is analogous to 2'-deoxyguanosine triphosphate (dGTP) and therefore incorporates into replicating DNA causing premature strand termination, replication failure and apoptosis (Figure 1) [2] .
![](https://static.igem.org/mediawiki/2017/1/1f/T--TECHNION-ISRAEL--guncic3.png)
Figure 1: The Ganciclovir System
Our goal is to add an additional cistron, which will code for HSV-TK, to our display mechanism. Accordingly, transfected HSCs expressing epitope will concurrently express HSV-TK. In the case of an allergic reaction, or patient dissatisfaction, treatment with Ganciclovir will induce apoptosis in all epitope expressing HSCs.
- Niculescu-Duvaz, Ion, et al. "Gene-directed enzyme prodrug therapy." Bioconjugate chemistry 9.1 (1998): 4-22.
- Zhang, Jin, Vijay Kale, and Mingnan Chen. "Gene-directed enzyme prodrug therapy." The AAPS journal 17.1 (2015): 102-110.
![](https://static.igem.org/mediawiki/2017/f/f9/T--TECHNION-ISRAEL--newUpAB.png)